BR9100519A - Composto,composicao farmaceutica,metodo para inibicao de colinesterase em um mamifero e metodo para melhorar a memoria ou tratar ou prevenir a doenca de alzheimer - Google Patents

Composto,composicao farmaceutica,metodo para inibicao de colinesterase em um mamifero e metodo para melhorar a memoria ou tratar ou prevenir a doenca de alzheimer

Info

Publication number
BR9100519A
BR9100519A BR919100519A BR9100519A BR9100519A BR 9100519 A BR9100519 A BR 9100519A BR 919100519 A BR919100519 A BR 919100519A BR 9100519 A BR9100519 A BR 9100519A BR 9100519 A BR9100519 A BR 9100519A
Authority
BR
Brazil
Prior art keywords
mammal
treat
disease
compound
pharmaceutical composition
Prior art date
Application number
BR919100519A
Other languages
English (en)
Inventor
Yuhpyng L Chen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9100519A publication Critical patent/BR9100519A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR919100519A 1990-02-08 1991-02-07 Composto,composicao farmaceutica,metodo para inibicao de colinesterase em um mamifero e metodo para melhorar a memoria ou tratar ou prevenir a doenca de alzheimer BR9100519A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47692890A 1990-02-08 1990-02-08

Publications (1)

Publication Number Publication Date
BR9100519A true BR9100519A (pt) 1991-10-29

Family

ID=23893824

Family Applications (1)

Application Number Title Priority Date Filing Date
BR919100519A BR9100519A (pt) 1990-02-08 1991-02-07 Composto,composicao farmaceutica,metodo para inibicao de colinesterase em um mamifero e metodo para melhorar a memoria ou tratar ou prevenir a doenca de alzheimer

Country Status (21)

Country Link
EP (1) EP0441517A3 (pt)
JP (1) JPH07119214B2 (pt)
KR (1) KR950013562B1 (pt)
CN (1) CN1054600A (pt)
AU (1) AU631723B2 (pt)
BR (1) BR9100519A (pt)
CA (1) CA2035805C (pt)
CS (1) CS29991A2 (pt)
DE (1) DE9101348U1 (pt)
EG (1) EG19644A (pt)
FI (1) FI910592A (pt)
HU (1) HUT70051A (pt)
IE (1) IE910402A1 (pt)
IL (1) IL97140A (pt)
NO (1) NO177534C (pt)
NZ (1) NZ237040A (pt)
PL (2) PL167078B1 (pt)
PT (1) PT96681A (pt)
TW (1) TW197442B (pt)
YU (1) YU21391A (pt)
ZA (1) ZA91916B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2807577B2 (ja) * 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
EP0475908A1 (de) * 1990-09-14 1992-03-18 Ciba-Geigy Ag Chromogene Lactamverbindungen und ihre Herstellung und Verwendung
TW263504B (pt) 1991-10-03 1995-11-21 Pfizer
TW248556B (pt) * 1993-01-18 1995-06-01 Takeda Pharm Industry Co
US5620973A (en) * 1993-11-30 1997-04-15 Takeda Chemical Industries, Ltd. Tetracyclic condensed heterocyclic compounds and their use
CN1572299A (zh) 1998-09-30 2005-02-02 武田药品工业株式会社 改善膀胱排泄能力的药物
ATE479686T1 (de) 2002-10-30 2010-09-15 Merck Frosst Canada Ltd Pyridopyrrolizin- und pyridoindolizinderivate
US7662831B2 (en) 2006-07-27 2010-02-16 Wyeth Llc Tetracyclic indoles as potassium channel modulators
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators
WO2012038966A1 (en) 2010-09-22 2012-03-29 Tyche Industries Ltd. Process for the preparation of donepezil intermediate
JOP20200030A1 (ar) * 2017-09-07 2020-02-12 Eisai R&D Man Co Ltd مركب خماسي الحلقة
EA202191966A1 (ru) 2019-03-05 2021-12-08 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Пентациклическое гетероциклическое соединение
AU2020233452A1 (en) 2019-03-05 2021-09-02 Eisai R&D Management Co., Ltd. Salt of pentacyclic compound and crystals thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3910947A (en) * 1969-07-24 1975-10-07 Sandoz Ag Preparation of imidazo{8 2,1-a{9 isoindoles
IT1199076B (it) * 1984-03-01 1988-12-30 Consiglio Nazionale Ricerche Derivati della fisostigmina con proprieta'di inibizione della aceticolinesterasi e relativo procedimento di produzione
US4563469A (en) * 1984-07-20 1986-01-07 Warner-Lambert Company Derivatives of N-[2-(tetrahydro-3,5-dioxo-1H-pyrrolizin-7a(5H)-yl)ethyl]amine as cognition activators
EP0187619A3 (de) * 1985-01-03 1987-08-26 Ciba-Geigy Ag 1,3-disubstituierte Tetrahydropyridine
US4791107A (en) * 1986-07-16 1988-12-13 Hoechst-Roussel Pharmaceuticals, Inc. Memory enhancing and analgesic 1,2,3,3A,8,8A-hexahydro-3A,8 (and) 1,3A,8)-di(and tri)methylpyrrolo(2,3-B)indoles, compositions and use
US4778812A (en) * 1987-06-12 1988-10-18 American Home Products Corporation 2,3-dihydro-9-methyl-1H-pyrrolo[1,2-a]indol-1-amines and derivatives thereof
EP0351283A1 (fr) * 1988-07-12 1990-01-17 Synthelabo Dérivés de [(pipéridinyl-4) méthyl]-2 dihydro-2,3 1H-isoindole et tétrahydro-2,3,4,5 1H-benzazépines, leur préparation et leur application en thérapeutique

Also Published As

Publication number Publication date
IL97140A (en) 1995-07-31
KR910015580A (ko) 1991-09-30
HUT70051A (en) 1995-09-28
PL167078B1 (pl) 1995-07-31
YU21391A (sh) 1994-01-20
HU910406D0 (en) 1991-08-28
FI910592A0 (fi) 1991-02-07
EP0441517A3 (en) 1992-08-19
PT96681A (pt) 1991-10-31
CN1054600A (zh) 1991-09-18
CS29991A2 (en) 1991-09-15
EP0441517A2 (en) 1991-08-14
NO177534C (no) 1995-10-04
IE910402A1 (en) 1991-08-14
NZ237040A (en) 1993-10-26
NO910473D0 (no) 1991-02-07
NO177534B (no) 1995-06-26
TW197442B (pt) 1993-01-01
PL288977A1 (en) 1992-01-13
JPH04234845A (ja) 1992-08-24
CA2035805C (en) 1995-06-27
PL166757B1 (pl) 1995-06-30
AU7087991A (en) 1991-08-29
JPH07119214B2 (ja) 1995-12-20
AU631723B2 (en) 1992-12-03
IL97140A0 (en) 1992-05-25
FI910592A (fi) 1991-08-09
EG19644A (en) 1995-08-30
ZA91916B (en) 1992-09-30
KR950013562B1 (ko) 1995-11-09
DE9101348U1 (de) 1991-06-06
NO910473L (no) 1991-08-09

Similar Documents

Publication Publication Date Title
LU91131I2 (fr) Duloxétine et ses sels d'addition acides pharmaceutiquement acceptables, et en particulier, chlorhydrate de duloxétine.
LV12438A (en) Metode of preventing and delyaing the onset of alzheimer's disease and composition thereof
BG95935A (bg) Метод и средство за приемане на дексмедетомидин директно през кожата
LU91452I2 (fr) "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"
BR9100519A (pt) Composto,composicao farmaceutica,metodo para inibicao de colinesterase em um mamifero e metodo para melhorar a memoria ou tratar ou prevenir a doenca de alzheimer
LU90334I2 (fr) Raloxifene et ses sels et dérivés pharmaceutiquement acceptables
KR970704445A (ko) 페노티아진 및/또는 티옥산틴을 사용한 알츠하이머 병의 치료 및/또는 예방 방법(methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
BR1100507A (pt) Processo para melhorar o desempenho de dissolução de um composto farmacêutico em uma forma de dosagem sólida.
OA09364A (fr) "Composition fongicide pour traitement de semences".
FI953915A (fi) Dupuytrenin taudin lievittämiseen
BR9100046A (pt) Derivados de azaoxindole,composicao farmaceutica e processo para o tratamento de mamiferos
BR9714145B1 (pt) composto ou seu sal farmaceuticamente aceitável e composição farmacêutica compreendendo o mencionado composto.
BR9607346A (pt) Composto utilizaç o de um composto composiç o farmacéutica e processo para o tratamento de um mamifero e para e preparaç o de compostos
MX9102701A (es) Derivados de 2-acilamido de 3,4-dihidro-3-oxo-quinoxalina que tienen actividad farmaceutica.
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
BR9407265A (pt) Composto composições farmacêuticas e métodos para tratamento de câncer em um mamifero
BR9401965A (pt) Composição farmecêutica antialérgica para administração tópica oftálmica e processo para produzir a mesma
BR9505995A (pt) Composto método para tratamentos e composição farmacêutica
ZA974506B (en) Medicament comprising a carnitine derivative for treating Alzheimer's disease in early-onset patients.
BR9611383A (pt) Peptídeo composição farmacêutica e processos para tratar um tumor em um mamífero e preparar os compostos
HU9700661D0 (en) Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer
EP0349589A4 (en) PHARMACOLOGICALLY ACTIVE CHOLINERGE PREPARATIONS AND METHOD FOR THE PRODUCTION AND THEIR USE FOR TREATING DISEASES.
NO913162L (no) Farmasoeytisk preparat for behandling av tonsillitt.
BR9808305A (pt) Forma hidratada cristalina, processo para a preparação da forma hidratada cristalina, composição farmacêutica, processo de tratamento de um mamìfero, e, processo de tratamento ou de prevenção de dor.
BR8904508A (pt) Composto,processo para sua preparacao,composicao e processo para o combate ou prevencao de doencas em plantas e aplicacao

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
FC Decision: refusal